Main Article Content
associated acute and chronic complications; thus, there is every possibility of administering other drugs along with the primary anti-diabetic agent, which may be the cause for a drug-drug interaction to occur. In the present study, the possible pharmacodynamic interaction was studied with amlodipine besylate and gliclazide in diabetic rats and healthy rabbits. The animals were divided into three groups. Gliclazide was studied at a dose of 1.44 mg/200 g and 5.6 mg/1.5 kg body weight in rats and rabbits respectively. Amlodipine besylate at a dose of 0.090 mg/200 g and 0.350 mg/1.5 kg body weight was used for the interaction study in rats and rabbits respectively. The drugs were administered orally and the blood samples were collected before and after administration of drug for a period of 16 h in rats and 24 h in rabbits. The serum samples were then subjected to glucose estimation by glucose peroxides method. The percentage reduction in blood glucose levels were calculated with respect to initial levels. Gliclazide showed a significant reduction of elevated and normal blood glucose
levels. The extent of blood glucose reduction was comparatively reduced in the case of combination therapy of amlodipine besylate and gliclazide. The study also suggests the necessity to readjust the dose of gliclazide when co-administered with amlodipine besylate.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Bastaki S. Diabetes mellitus and its treatment. Int J Diabetes Metab
Hardman JG, Limbird LE. Goodman and Gilmanâ€™s The pharmacological
basics of therapeutics. 9th ed. New York: McGraw Hill; 1996. p. 1493.
Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at
onset, and development of microvascular complications in childhood-
onset type 1 diabetes: A population-based study in northern Sweden.
Diabetes Care 2004;27:955-62.
Saely CH, Aczel S, Marte T. Cardiovascular complications in type 2
diabetes mellitus depend on the coronary angiographic state rather
than on the diabetes state. Diabetologia 2004;47:145-6.
David BT, Remington: The science and practice of pharmacy. 21st ed.
Philadelphia: Lippincott Williams and Wilkins; 2005. p. 1889.
Mohan V. Handbook of diabetes mellitus. 2nd ed. Chennai: MV Diabetes
Specialities Centre and Madras Diabetes Research Foundation;
McEvoy GK. AHFS drug information. Bethesda: American Society of
Health-system Pharmacists, Inc; 2004. p. 3038.
Swami AM, Shetty SR, Kumar SM, Rao NV. A study on drug-drug
interaction of roxithromycin and antidiabetic drugs. Indian Drugs
Dhanabal SP. Antihyperglycemic activity of Polygala arvensis in alloxan
diabetic rats. Indian Drugs 2004;41:690-5.
Setty SR. Influence of itraconazole on sulfonylureas-induced
hypoglycemia in diabetic rats. Indian J Pharm Sci 2005;67:677-80.
Trinder P. Determination of glucose in blood using glucose oxidase
with an alternative glucose acceptor. Ann Clin Biochem 1969;6:24-7.
Satyanarayana S. Influence of quinidine, selegiline and amphotericin-B
on the pharmacokinetics and pharmacodynamics of Tolbutamide in
rabbits. Indian Drugs 1998;35:640-4.
Bressler R, Johnson DG. Pharmacological regulation of blood glucose
levels in non-insulin dependent diabetes mellitus. Arch Intern Med
Chiasson JL. Acarbose for prevention of type 2 diabetes mellitus. Am
J Med 1991;90:450.
Silva EM. Ultrasonographic abnormalities of the pancreas in IDDM and
NIDDM patients. Diabetes Care 1993;16:1296-7.
Satyanarayana S, Eswar kumar K, Rajasekar J, Thomas L, Rajanna S,
Rajanna B. Influence of aqueous extract of Fenugreek- seed powder
on the Pharmacodynamics and Pharmacokinetics of Gliclazide in rats
and rabbits. Therapy 2007;4:457-463.